$1.34
4.29% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US54303L1044
Symbol
LGVN
Sector
Industry

Longeveron Inc - Ordinary Shares - Class A Stock price

$1.34
-0.18 11.84% 1M
-0.51 27.57% 6M
-0.39 22.54% YTD
+0.11 8.50% 1Y
-80.56 98.36% 3Y
-98.66 98.66% 5Y
-98.66 98.66% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.06 4.29%
ISIN
US54303L1044
Symbol
LGVN
Sector
Industry

Key metrics

Market capitalization $20.11m
Enterprise Value $7.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.17
P/S ratio (TTM) P/S ratio 9.02
P/B ratio (TTM) P/B ratio 1.17
Revenue growth (TTM) Revenue growth 127.51%
Revenue (TTM) Revenue $2.23m
EBIT (operating result TTM) EBIT $-17.61m
Free Cash Flow (TTM) Free Cash Flow $-16.15m
Cash position $14.33m
EPS (TTM) EPS $-2.77
P/E forward negative
P/S forward 11.32
EV/Sales forward 3.99
Short interest 5.31%
Show more

Is Longeveron Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Longeveron Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Longeveron Inc - Ordinary Shares - Class A forecast:

Buy
100%

Financial data from Longeveron Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2.23 2.23
128% 128%
100%
- Direct Costs 1.52 1.52
4% 4%
68%
0.71 0.71
245% 245%
32%
- Selling and Administrative Expenses 9.88 9.88
13% 13%
443%
- Research and Development Expense 7.31 7.31
3% 3%
328%
-16 -16
15% 15%
-739%
- Depreciation and Amortization 1.13 1.13
18% 18%
51%
EBIT (Operating Income) EBIT -18 -18
14% 14%
-790%
Net Profit -17 -17
19% 19%
-759%

In millions USD.

Don't miss a Thing! We will send you all news about Longeveron Inc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Longeveron Inc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
about 15 hours ago
Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
Neutral
GlobeNewsWire
9 days ago
Longeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer's disease and HLHS, a rare pediatric disease and orphan-designated indication MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company develo...
Neutral
Seeking Alpha
11 days ago
Longeveron Inc. (NASDAQ:LGVN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Derek Cole - Investor Relations-Advisory Solutions Joshua Hare - Co-Founder, Chief Science Officer & Chairman of the Board Wa'el Hashad - Chief Executive Officer Nataliya Agafonova - Chief Medical Officer Devin Blass - Chief Technology Officer Lisa Locklear - Chief Financial Officer Confe...
More Longeveron Inc - Ordinary Shares - Class A News

Company Profile

Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.

Head office United States
CEO Mohamed Hashad
Employees 26
Founded 2014
Website www.longeveron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today